RG6501 (OpRegen®) Full Phase 1/2a Results to Be Featured at 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Allen C. Ho, M.D., FACS

by Business Wire • 2022/03/14 • 0 Comments

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that full results from a Phase 1/2a clinical study of RG6501 (OpRegen®), a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD), will be presented at the 2022 Association for Research in Vision an

← Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink™ Therapy

ANJAC Health & Beauty Strengthens Its Presence in North America and Its Pharmaceutical Activities with the Acquisition of Pillar5 Pharma →

Post navigation